CA2724915A1 - Interleukin-21 receptor binding proteins - Google Patents

Interleukin-21 receptor binding proteins Download PDF

Info

Publication number
CA2724915A1
CA2724915A1 CA2724915A CA2724915A CA2724915A1 CA 2724915 A1 CA2724915 A1 CA 2724915A1 CA 2724915 A CA2724915 A CA 2724915A CA 2724915 A CA2724915 A CA 2724915A CA 2724915 A1 CA2724915 A1 CA 2724915A1
Authority
CA
Canada
Prior art keywords
antigen
binding
binding protein
binding fragment
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2724915A
Other languages
English (en)
French (fr)
Inventor
Laird Bloom
Davinder Gill
Yulia Vugmeyster
Deborah A. Young
David Lowe
Viia Valge-Archer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Wyeth LLC
Original Assignee
MedImmune Ltd
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2724915(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune Ltd, Wyeth LLC filed Critical MedImmune Ltd
Publication of CA2724915A1 publication Critical patent/CA2724915A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2724915A 2008-05-23 2009-05-26 Interleukin-21 receptor binding proteins Abandoned CA2724915A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23
US61/055,500 2008-05-23
PCT/US2009/045182 WO2009143523A1 (en) 2008-05-23 2009-05-26 Interleukin-21 receptor binding proteins

Publications (1)

Publication Number Publication Date
CA2724915A1 true CA2724915A1 (en) 2009-11-26

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724915A Abandoned CA2724915A1 (en) 2008-05-23 2009-05-26 Interleukin-21 receptor binding proteins

Country Status (20)

Country Link
US (2) US8163884B2 (enExample)
EP (1) EP2297199A1 (enExample)
JP (1) JP2011523849A (enExample)
KR (1) KR20110040773A (enExample)
CN (1) CN102105491A (enExample)
AR (1) AR071885A1 (enExample)
AU (1) AU2009248809A1 (enExample)
CA (1) CA2724915A1 (enExample)
CL (1) CL2009001284A1 (enExample)
CO (1) CO6382184A2 (enExample)
IL (1) IL209328A0 (enExample)
MX (1) MX2010012811A (enExample)
MY (1) MY149448A (enExample)
NZ (1) NZ589330A (enExample)
PE (1) PE20100141A1 (enExample)
RU (1) RU2010152690A (enExample)
SA (1) SA109300315B1 (enExample)
TW (1) TW201000129A (enExample)
WO (1) WO2009143523A1 (enExample)
ZA (1) ZA201008335B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
EP2518084B1 (en) * 2009-12-25 2016-11-30 Sekisui Medical Co., Ltd. Method for measuring human insulin and measurement reagent
EP2545080B1 (en) * 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
UA84387C2 (ru) 1999-03-09 2008-10-27 Займодженетикс, Инк. Человеческий цитокин как лиганд зальфа рецептора и его применение
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ATE346864T1 (de) 2000-05-11 2006-12-15 Genetics Inst Llc Mu-1, ein mitglied der cytokine rezeptor familie
EP2130919A1 (en) * 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
RU2005132458A (ru) * 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
MX2007001509A (es) 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
AR071885A1 (es) 2010-07-21
IL209328A0 (en) 2011-01-31
CN102105491A (zh) 2011-06-22
AU2009248809A1 (en) 2009-11-26
CL2009001284A1 (es) 2009-11-27
WO2009143523A1 (en) 2009-11-26
US20120264919A1 (en) 2012-10-18
JP2011523849A (ja) 2011-08-25
EP2297199A1 (en) 2011-03-23
MY149448A (en) 2013-08-30
SA109300315B1 (ar) 2012-08-28
ZA201008335B (en) 2014-04-30
PE20100141A1 (es) 2010-02-22
RU2010152690A (ru) 2012-06-27
MX2010012811A (es) 2011-05-19
KR20110040773A (ko) 2011-04-20
TW201000129A (en) 2010-01-01
NZ589330A (en) 2012-12-21
US20090298167A1 (en) 2009-12-03
CO6382184A2 (es) 2012-02-15
US8163884B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
US8163884B2 (en) Interleukin-21 receptor binding proteins
KR102572091B1 (ko) 항 gprc5d 항체, gprc5d 및 cd3에 결합하는 이중특이성 항원 결합 분자, 및 이들의 용도
US8178097B2 (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
AU2016239858B2 (en) Antibodies to canine interleukin-4 receptor alpha
KR101605908B1 (ko) Ｃｄ154에 특이적으로 결합하는, 항체, 항체 유도체 및 항체 단편을 포함하는 결합 단백질, 및 그의 용도
WO2022042690A1 (zh) Ccr8抗体及其应用
CA2480059C (en) Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
JP2022008601A (ja) 二重特異性結合タンパク質およびその使用
JP2021508449A (ja) Ｃｈ３ドメイン中に挿入された特異的ｐｄ−ｌ１結合配列
SA07280062B1 (ar) الاجسام المضادة لـ il -22 الآدمى و استخداماتها
KR20240021194A (ko) Il-2 및 항-pd-1 기반의 치료제 및 이의 이용 방법
CA2991634A1 (en) Multivalent and multispecific dr5-binding fusion proteins
US20250340654A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha ii
KR20240026496A (ko) 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체
US20250282881A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
EP2438084A2 (en) Antibodies against human ccn1 and uses thereof
KR20160125965A (ko) 신규 인간 tlr2 및 인간 tlr4에 결합하는 이중 특이적 항체
HK1157358A (en) Interleukin-21 receptor binding proteins
US20230203170A1 (en) Anti-CSF1R Molecules and Use Thereof
CN118894934A (zh) 抗人il-15的抗体及其用途
HK1157220A (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
CN120152991A (zh) 靶向人源ror1的单域抗体
WO2024153163A1 (zh) 抗cd93抗体及其应用
HK40086025A (en) Anti-human nr1 antibody derivative

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150526